Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT02684032

Public ClinicalTrials.gov record NCT02684032. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 7:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

PHASE 1B STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OF GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AND EITHER LETROZOLE OR FULVESTRANT IN WOMEN WITH METASTATIC OR LOCALLY ADVANCED/RECURRENT BREAST CANCER (MBC)

Study identification

NCT ID
NCT02684032
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Celcuity Inc
Industry
Enrollment
141 participants

Conditions and interventions

Conditions

Interventions

  • Gedatolisib Drug
  • Palbociclib Drug
  • Letrozole Drug
  • Fulvestrant Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 13, 2016
Primary completion
Jan 18, 2022
Completion
Jan 18, 2022
Last update posted
Jul 26, 2022

2016 – 2022

United States locations

U.S. sites
41
U.S. states
14
U.S. cities
20
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35233
University of Alabama at Birmingham Birmingham Alabama 35249
Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc. Corona California 92879
Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc. Fountain Valley California 92708
Keck Hospital of USC - Norris Healthcare Center (HC3) Los Angeles California 90033
Keck Hospital of USC Los Angeles California 90033
LAC+USC Medical Center Los Angeles California 90033
USC/Norris Comprehensive Cancer Center / Investigational Drug Services Los Angeles California 90033
USC/Norris Comprehensive Cancer Center Los Angeles California 90033
Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc. Riverside California 92501
UCSF - Helen Diller Family Comprehensive Cancer Center San Francisco California 94115
UCSF - Helen Diller Family Comprehensive Cancer Center San Francisco California 94158
University of Colorado Hospital - Anschutz Inpatient Pavilion (AiP) Aurora Colorado 80045
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP) Aurora Colorado 80045
University of Colorado Hospital - Clinical Trials Office (CTO) Aurora Colorado 80045
University of Colorado Hospital- Anschutz Cancer Pavilion (ACP) Aurora Colorado 80045
Moffitt Cancer Center Richard M Schulze Family Foundation Outpatient Center at McKinley Campus Tampa Florida 33612
Moffitt Cancer Center Tampa Florida 33612
Emory University Hospital Midtown Atlanta Georgia 30308
Emory University Hospital Atlanta Georgia 30322
The Emory Clinic Atlanta Georgia 30322
Winship Cancer Institute Atlanta Georgia 30322
Massachusetts General Hospital Boston Massachusetts 02114
University of Michigan Ann Arbor Michigan 48109
Karmanos Cancer Institute Detroit Michigan 48201
Karmanos Cancer Institute Farmington Hills Michigan 48334
UNC Cancer Hospital Infusion Pharmacy Chapel Hill North Carolina 27514
UNC Hospitals, The University of North Carolina at Chapel Hill Chapel Hill North Carolina 27514
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210
The Ohio State University Wexner Medical Center James Cancer Hospital Columbus Ohio 43210
Stefanie Spielman Comprehensive Breast Cancer Columbus Ohio 43212
Thomas Jefferson University - Clinical and Regulatory Philadelphia Pennsylvania 19107
Thomas Jefferson University Philadelphia Pennsylvania 19107
Vanderbilt Breast Center at One Hundred Oaks Nashville Tennessee 37204
Henry-Joyce Cancer Clinic Nashville Tennessee 37232
The University of Texas MD Anderson Cancer Center Houston Texas 77030
U.T. MD Anderson Cancer Center Houston Texas 77030
Virginia Cancer Specialists, PC Fairfax Virginia 22031
Seattle Cancer Care Alliance (SCCA) Investigational Drug Services Seattle Washington 98109
Seattle Cancer Care Alliance Seattle Washington 98109
University of Washington Medical Center Seattle Washington 98195

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02684032, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 26, 2022 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02684032 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →